Therakos Bought by Mallinckrodt for $1.33 Billion

Mallinckrodt (NYSE:MNK) has announced that it will buy Therakos, a privately held immunotherapy company, for $1.33 billion.
According to Pharmaceutical Processing:

Therakos’ Photopheresis system collects immune cells from a patient’s blood, treats the cells with ultraviolet light to activate them, and returns them to the patient’s body so they can attack a disease. In the U.S. its system is used to treat skin problems caused by cutaneous T-cell lymphoma, a type of blood cancer that involves the skin. It’s approved for patients who haven’t been helped by other treatments. The device has been approved for conditions like Crohn’s disease and organ transplants in other countries.